Dow Jones

40,003.59

0.34%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

CLVS

Clovis Oncology (CLVS)

Clovis Oncology Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CLVS

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
01/05/2023	15:17	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CLVS	Clovis Oncology Inc
10/02/2023	08:49	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CLVS	Clovis Oncology Inc
29/12/2022	08:36	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:CLVS	Clovis Oncology Inc
12/12/2022	05:54	Dow Jones News	Clovis Oncology Shares Fall Premarket After Bankruptcy Filing	NASDAQ:CLVS	Clovis Oncology Inc
11/12/2022	23:18	Business Wire	Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286	NASDAQ:CLVS	Clovis Oncology Inc
09/11/2022	07:12	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:CLVS	Clovis Oncology Inc
03/11/2022	15:18	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CLVS	Clovis Oncology Inc
27/10/2022	16:05	Business Wire	Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat	NASDAQ:CLVS	Clovis Oncology Inc
17/10/2022	02:45	Business Wire	Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress	NASDAQ:CLVS	Clovis Oncology Inc
03/10/2022	06:00	Business Wire	TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations	NASDAQ:CLVS	Clovis Oncology Inc
21/09/2022	07:00	Business Wire	Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement	NASDAQ:CLVS	Clovis Oncology Inc
13/09/2022	07:00	Business Wire	Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer	NASDAQ:CLVS	Clovis Oncology Inc
12/09/2022	06:55	TipRanks	Clovis (NASDAQ:CLVS) Jumps After Rubraca Shows Progression-Free Survival in Ovarian Cancer	NASDAQ:CLVS	Clovis Oncology Inc
11/09/2022	09:30	Business Wire	Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups	NASDAQ:CLVS	Clovis Oncology Inc
09/08/2022	05:16	TipRanks	H.C. Wainwright Remains a Hold on Clovis Oncology (CLVS)	NASDAQ:CLVS	Clovis Oncology Inc
08/08/2022	07:00	Business Wire	Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs	NASDAQ:CLVS	Clovis Oncology Inc
22/07/2022	08:35	TipRanks	H.C. Wainwright Maintains a Hold Rating on Clovis Oncology (CLVS)	NASDAQ:CLVS	Clovis Oncology Inc
20/07/2022	17:06	Business Wire	CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8	NASDAQ:CLVS	Clovis Oncology Inc
20/07/2022	15:00	Business Wire	Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8	NASDAQ:CLVS	Clovis Oncology Inc
08/07/2022	15:58	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:CLVS	Clovis Oncology Inc
07/07/2022	15:35	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:CLVS	Clovis Oncology Inc
28/06/2022	07:31	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:CLVS	Clovis Oncology Inc
14/06/2022	13:00	Business Wire	Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting	NASDAQ:CLVS	Clovis Oncology Inc
06/06/2022	10:55	TipRanks	Clovis Oncology (CLVS) Gets a Hold Rating from H.C. Wainwright	NASDAQ:CLVS	Clovis Oncology Inc
06/06/2022	07:00	Business Wire	Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status	NASDAQ:CLVS	Clovis Oncology Inc
05/05/2022	07:00	Business Wire	Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference	NASDAQ:CLVS	Clovis Oncology Inc
05/05/2022	05:17	TipRanks	Clovis Oncology (CLVS) Receives a Buy from H.C. Wainwright	NASDAQ:CLVS	Clovis Oncology Inc
04/05/2022	07:00	Business Wire	Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs	NASDAQ:CLVS	Clovis Oncology Inc
28/04/2022	07:00	Business Wire	Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting	NASDAQ:CLVS	Clovis Oncology Inc
27/04/2022	15:06	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:CLVS	Clovis Oncology Inc